Evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
anticocaine	anticocaine	O	O	O	O
monoclonal	monoclonal	O	O	O	O
antibody	antibody	O	O	O	O
GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
an	an	O	O	O	O
immunotherapy	immunotherapy	O	O	O	O
for	for	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
overdose	overdose	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
illicit	illicit	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
continues	continues	O	O	O	O
in	in	O	O	O	O
epidemic	epidemic	O	O	O	O
proportions	proportions	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
overdose	overdose	O	DISEASE	OTHERS	I
remains	remains	O	O	O	O
elusive	elusive	O	O	O	O
.	.	O	O	O	O

Current	current	O	O	O	O
protein-based	protein-based	O	O	O	O
technology	technology	O	O	O	O
offers	offers	O	O	O	O
a	a	O	O	O	O
new	new	O	O	O	O
therapeutic	therapeutic	O	O	O	O
venue	venue	O	O	O	O
by	by	O	O	O	O
which	which	O	O	O	O
antibodies	antibodies	O	O	O	O
bind	bind	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
blood	blood	O	O	O	O
stream	stream	O	O	O	O
,	,	O	O	O	O
inactivating	inactivating	O	O	O	O
its	its	O	O	O	O
toxic	toxic	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
therapeutic	therapeutic	O	O	O	O
potential	potential	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
anticocaine	anticocaine	O	O	O	O
antibody	antibody	O	O	O	O
GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
examined	examined	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
model	model	O	O	O	O
of	of	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
overdose	overdose	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Swiss	swiss	O	O	O	O
albino	albino	O	O	O	O
mice	mice	O	O	O	O
prepared	prepared	O	O	O	O
with	with	O	O	O	O
intrajugular	intrajugular	O	O	O	O
catheters	catheters	O	O	O	O
were	were	O	O	O	O
tested	tested	O	O	O	O
in	in	O	O	O	O
photocell	photocell	O	O	O	O
cages	cages	O	O	O	O
after	after	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
93	93	O	O	O	O
mg/kg	mg/kg	O	O	O	O
(	(	O	O	O	O
LD50	ld50	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
infusions	infusions	O	O	O	O
ranging	ranging	O	O	O	O
from	from	O	O	O	O
30	30	O	O	O	O
to	to	O	O	O	O
190	190	O	O	O	O
mg/kg	mg/kg	O	O	O	O
.	.	O	O	O	O

GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
delivered	delivered	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
before	before	O	O	O	O
,	,	O	O	O	O
concomitantly	concomitantly	O	O	O	O
or	or	O	O	O	O
3	3	O	O	O	O
min	min	O	O	O	O
after	after	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Significant	significant	O	O	O	O
blockade	blockade	O	O	O	O
of	of	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
higher	higher	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
190	190	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
where	where	O	O	O	O
premorbid	premorbid	O	O	O	O
behaviors	behaviors	O	O	O	O
were	were	O	O	O	O
reduced	reduced	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
40	40	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
up	up	O	O	O	O
to	to	O	O	O	O
77	77	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
death	death	O	DISEASE	OTHERS	I
by	by	O	O	O	O
72	72	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Importantly	importantly	O	O	O	O
,	,	O	O	O	O
GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
prevented	prevented	O	O	O	O
death	death	O	DISEASE	OTHERS	I
even	even	O	O	O	O
post-cocaine	post-cocaine	O	O	O	O
injection	injection	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
support	support	O	O	O	O
the	the	O	O	O	O
important	important	O	O	O	O
potential	potential	O	O	O	O
of	of	O	O	O	O
GNC92H2	gnc92h2	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
therapeutic	therapeutic	O	O	O	O
tool	tool	O	O	O	O
against	against	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
overdose	overdose	O	DISEASE	OTHERS	I
.	.	O	O	O	O

